Fig. 8
Oncolytic virus-mediated immunotherapy combined with low-dose radiation targeted to secondary metastatic sites presents a novel treatment strategy for advanced uveal melanoma (particularly affecting the liver), as well as cutaneous melanoma (particularly affecting the brain)